MATERIAL FACT
HYPERMARCAS S.A. (the "Company" or "Hypermarcas"), in compliance with the provisions of Art. 157, § 4th, of Law No. 6,404, of December 15, 1976, as amended and currently in force, in CVM Instruction No. 358, of January 03, 2002, as amended, and in CVM Instruction No. 480, of December 7, 2009, and, in line with the best corporate governance practices, updates its guidance to the market for the year of 2015.
In view of the analysis of the macroeconomic environment and the dynamics in the markets in which Hypermarcas operates, the Company introduces an Adjusted EBITDA guidance around R$1.2 billion for the year of 2015.
The present notice includes projections reflecting solely the perception of the Company's Management about factors that may impact its performance, such as general economic conditions, in addition to the dynamics of its markets and its operations, being therefore subject to risks and uncertainties. Any modification in such perception about such factors may cause the guidance to be amended.
São Paulo, February 6, 2015
HYPERMARCAS S.A. Breno Toledo Pires de Oliveira Investors' Relations Officer
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
HYPERA S.A. 
